Lenalidomide (Revlimid®) in patients with cutaneous T-cell lymphoma. Hematology Meeting Reports, [S. l.], v. 3, n. 1, 2009. DOI: 10.4081/hmr.v3i1.546. Disponível em: https://journals.pagepress.org/hmr/article/view/546. Acesso em: 8 aug. 2025.